Strikingly, increases in two regulatory B-cell subsets, CD19+B220+CD5+CD1d+ and CD19-B220+CD5+CD1d-, were observed in the livers of mice subjected to MASLD. This evidence concerns the gene CD19 and metabolic dysfunction-associated steatotic liver disease.